Correlations between Electrophysiological Parameters, Lymphocyte Distribution and Cytokine Levels in Patients with Chronic Demyelinating Inflammatory Polyneuropathy

Dziadkowiak, Edyta; Moreira, Helena; Wieczorek, Małgorzata; Budrewićz, Sławomir; Barg, Ewa; Koszewicz, Magdalena

doi:10.3390/jpm11080766

Cited by 4 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, CD3 + T cells were significantly decreased in CIDP patients with IVIg or steroid treatment compared to the untreated group, as previously reported [ 24 , 33 ]. By contrast, immune treatments failed to make a significant reversion in B-cell dysregulation in our CIDP patients.…”

Section: Discussionsupporting

confidence: 90%

“…TNF-α exerts toxic effects on myelin and Schwann cells by increasing vascular permeability and breaking the blood-nerve barrier [ 42 ]. Compatible with our findings, some previous studies also reported increased serum TNF-α levels in CIDP by ELISA [ 33 , 42 , 43 ] and a relationship between disease severity and TNF-α levels [ 43 ].…”

Section: Discussionsupporting

confidence: 86%

“…The CD19 + B-cell percentages in untreated CIDP patients and CIDP patients with steroid treatment were significantly lower than in healthy controls, as previously reported [ 33 ]. However, the percentages of CD19 + B-cells in CIDP patients with IVIg treatment were significantly increased compared to untreated and healthy controls, as well as patients under steroid treatment, in contrast to the previous two studies including dysimmune neuropathy patients treated with IVIg [ 24 , 25 ].…”

Section: Discussionsupporting

confidence: 85%

See 2 more Smart Citations

Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes

Ozdag Acarli,

Tuzun,

Sanli

et al. 2023

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyneuropathy (CIDP), a common and treatable autoimmune neuropathy, is frequently misdiagnosed. The aim of this study is to evaluate the relationship between immunological markers and clinical outcome measures in a mixed cohort of patients with typical CIDP and CIDP variants at different disease stages. Twenty-three typical, 16 multifocal and five distal CIDP patients were included. Twenty-five sex and age-matched healthy controls and 12 patients with Charcot–Marie–Tooth type 1A (CMT1A) disease served as controls. Peripheral B-cell populations were analyzed by flow cytometry. IL6, IL10, TNFA mRNA and mir-21, mir-146a, and mir-155-5p expression levels were evaluated by real-time polymerase chain reaction in peripheral blood mononuclear cells (PBMC) and/or skin biopsy specimens. Results were then assessed for a possible association with clinical disability scores and intraepidermal nerve fiber densities (IENFD) in the distal leg. We detected a significant reduction in naive B cells (P ≤ 0.001), plasma cells (P ≤ 0.001) and regulatory B cells (P < 0.05), and an elevation in switched memory B cells (P ≤ 0.001) in CIDP compared to healthy controls. CMT1A and CIDP patients had comparable B-cell subset distribution. CIDP cases had significantly higher TNFA and IL10 gene expression levels in PBMC compared to healthy controls (P < 0.05 and P ≤ 0.01, respectively). IENFDs in the distal leg showed a moderate negative correlation with switched memory B-cell ratios (r = –0.51, P < 0.05) and a moderate positive correlation with plasma cell ratios (r = 0.46, P < 0.05). INCAT sum scores showed a moderate positive correlation with IL6 gene expression levels in PBMC (r = 0.54, P < 0.05). Altered B-cell homeostasis and IL10 and TNFA gene expression levels imply chronic antigen exposure and overactivity in the humoral immune system, and seem to be a common pathological pathway in both typical CIDP and CIDP variants.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes

Ozdag Acarli,

Tuzun,

Sanli

et al. 2023

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Electrophysiological parameters in CIDP patients were also found to be closely related to the autoimmune process. All these studies may contribute to a better understanding of the pathomechanism of CIDP [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Dziadkowiak

Baczyńska

Wieczorek

et al. 2023

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

Background. MicroRNAs are endogenous, small noncoding RNA molecules that play a pivotal role in the regulation of gene expression. MicroRNAs are involved in many biological processes such as proliferation, cell differentiation, neovascularization, and apoptosis. Studies on microRNA expression may contribute to a better understanding of the pathomechanism of chronic inflammatory demyelinating polyneuropathy (CIDP) and consequently enable the development of new therapeutic measures using antisense miRNAs (antagomirs). In this study, we evaluated the level of miR-31-5p in the serum of patients with CIDP and its correlation with the miR-31-5p level and clinical presentation and electrophysiological and biochemical parameters. Methods. The study group consisted of 48 patients, mean age 61.60 ± 11.76 , who fulfilled the diagnostic criteria of a typical variant of CIDP. The expression of miR-31-5p in patient serum probes was investigated by droplet digital PCR. The results were correlated with neurophysiological findings and the patient’s clinical and biochemical parameters. Results. The mean copy number of miRNA-31 in 100 μl serum was 1288.64 ± 2001.02 in the CIDP group of patients, while in the control group, it was 3743.09 ± 4026.90 . There was a significant positive correlation (0.426) between IgIV treatment duration and miR-31-5p expression. Patients without IgIV treatment showed significantly lower levels of miR-31 compared to the treated group ( 259.44 ± 304.02 vs. 1559.48 ± 2168.45 ; p = 0.002 ). The group of patients with body weight > 80 kg showed statistically significantly lower levels of miRNA-31-5p than the patients with lower body weight ( 934.37 ± 1739.66 vs. 1784.62 ± 2271.62 , respectively; p = 0.014 ). Similarly, the patients with elevated cerebrospinal fluid (CSF) protein levels had significantly higher miRNA-31-5p expression than those with normal protein levels ( 1393.93 ± 1932.27 vs. 987.38 ± 2364.10 , respectively; p = 0.044 ). Conclusion. The results may support the hypothesis that miR-31-5p is strongly involved in the autoimmune process in CIDP. The positive correlation between higher miR-31-5p levels and duration of IVIg treatment may be an additional factor explaining the efficacy of prolonged IVIg therapy in CIDP.

show abstract

“…Tumor necrosis factor alpha (TNF-α) was the most studied cytokine, measured in 383 CIDP patients across 20 studies, with 18 including control subjects 15,17,18,25,29,34,35,42,43,44,45,49,50,56,60,63,65,67 and 2 without. 40,54 In 50% of the studies involving 251 tested CIDP patients, 15,25,29,34,35,50,63,49,44 TNF-α levels were found to be elevated compared to controls.…”

Section: Tumor Necrosis Factor Alphamentioning

confidence: 99%

Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review

Cutellè,

De Lorenzo,

Doneddu

et al. 2024

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Advances in the understanding of cytokines have revolutionized mechanistic treatments for chronic inflammatory and autoimmune diseases, as exemplified by rheumatoid arthritis. We conducted a systematic literature review on the role of cytokines and chemokines in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). Ovid Medline, EMBASE and Web of Science were searched until August 31, 2022 for human studies investigating cytokines levels in CIDP or MMN. Fifty‐five articles on 1061 CIDP patients and 86 MMN patients were included, with a median of 18 patients per study (range 3–71). Studies differed in the inclusion criteria, type of assay, manufacturer, control subjects, and tested biological material. Only a minority of studies reported data on disease activity. Interleukin (IL)‐6, IL‐17, CXCL10, and tumor necrosis factor alpha (TNF‐α), were elevated in CIDP compared to controls in most of the studies. IL‐6 and TNF‐α levels are also correlated with disability. In MMN patients, IL‐1Ra was elevated in the majority of the reports. While acknowledging the challenges in comparing studies and the various limitations of the studies, including small patient numbers, particularly in MMN, our review suggests that IL‐6, IL‐17, CXCL10, and TNF‐α might play a role in CIDP pathogenesis. Larger studies are needed in MMN.

show abstract

Correlations between Electrophysiological Parameters, Lymphocyte Distribution and Cytokine Levels in Patients with Chronic Demyelinating Inflammatory Polyneuropathy

Cited by 4 publications

References 41 publications

Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes

Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes

miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review

Contact Info

Product

Resources

About